Ultragenyx Pharmaceutical (RARE) Finished Goods (2017 - 2026)

Ultragenyx Pharmaceutical (RARE) has reported Finished Goods for 10 consecutive years, with $22.0 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Finished Goods fell 4.84% year-over-year to $22.0 million; the TTM figure through Mar 2026 stood at $22.0 million (down 4.84% YoY), while the FY2025 annual figure was $25.0 million, up 8.7% from the prior year.
• Finished Goods slipped to $22.0 million in Q1 2026 per RARE's latest filing, from $25.0 million in the prior quarter.
• Across five years, Finished Goods topped out at $26.7 million in Q2 2025 and bottomed at $4.9 million in Q2 2022.
• Historically, Finished Goods has averaged $15.8 million across 5 years, with a median of $14.9 million in 2024.
• Annual changes were most pronounced in 2022 — Finished Goods retreated 13.08% — and 2023, when it surged 107.99%.
• Ultragenyx Pharmaceutical's Finished Goods stood at $9.3 million in 2022, then soared by 62.82% to $15.1 million in 2023, then soared by 52.22% to $23.0 million in 2024, then grew by 8.7% to $25.0 million in 2025, then fell by 12.0% to $22.0 million in 2026.
• Business Quant data shows RARE's Finished Goods at $22.0 million in Q1 2026, $25.0 million in Q4 2025, and $23.0 million in Q3 2025.